Pulmonary embolism (PE) is associated with high morbidity and mortality, making it a major contributor to global disease burden. [1,2] Thus, current guideline recommendations emphasize the importance of early risk stratification in the heterogeneous group of normotensive PE patients to guide therapeutic decision making. [2] The main determinant of adverse outcomes in PE patients is right ventricular (RV) failure due to the occlusion of the pulmonary vasculature by embolised thrombi, that may progress to manifest obstructive shock.
